Author: Aspire Biopharma Holdings, Inc.

Strategic inventory of 100,000 20-packs now available to meet increasing demand for rapid-onset sublingual caffeine technology

ESTERO, FL / ACCESS Newswire / January 22, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP), a leader in innovative patent-pending sublingual delivery technologies, today announced it has taken delivery of two million units of its flagship caffeine supplement, BUZZ BOMB™.

This delivery marks a critical milestone in Aspire’s commercialization strategy, introducing a comprehensive brand relaunch and redesigned packaging. The new aesthetic is engineered for high-impact shelf presence and digital engagement, emphasizing the product’s core advantages: nearly instant energy, precise 50mg dosing, and the convenience of sublingual absorption.

BUZZ BOMB™ Newly Designed Packaging

Unlike traditional energy drinks or pills, BUZZ BOMB™–a dry powder sprinkled under the tongue from a single-serving stick pack–utilizes a proprietary sublingual format that delivers pure caffeine quickly without the hassle of mixing with water, without drinking typical caffeine sources like energy drinks, coffee, or soda.

“This significant inventory delivery of BUZZ BOMB™ is expected to support the launching of our expanded consumer strategy,” said Kraig Higginson, Interim CEO of Aspire Biopharma. “By combining our new production capacity with a modernized brand identity, BUZZ BOMB™ is uniquely positioned to scale. Together with our new online e-commerce website and refreshed packaging design, BUZZ BOMB™ is primed to capture significant market share by introducing our revolutionary sublingual technology to a wider audience.”

To drive growth following this delivery, Aspire plans to launch an aggressive marketing campaign featuring:

• Expanded Digital Marketing: Targeted campaigns across high-traffic social platforms.

• Influencer Partnerships: Collaborations with performance-focused creators in the fitness and healthy lifestyle sectors.

• DTC Optimization: Streamlined purchasing via the BUZZ BOMB™ official storefront.

The Company is concurrently evaluating new retail partnerships and wholesale distribution channels to maximize the reach of the refreshed 20-pack configurations.

About BUZZ BOMB™

BUZZ BOMB™ is a proprietary sublingual caffeine supplement developed by Aspire Biopharma that features 50mg of caffeine and is currently offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha). Designed for athletes, professionals, and the everyday person needing a rapid cognitive boost, BUZZ BOMB™ provides a precise dose of caffeine that bypasses the GI tract for faster onset and smoother energy. To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com. New flavors are under development and will be released in the coming months.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs and supplements to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

• New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized anxiety disorders

• Alprazolam, sold under the brand name Xanax® among others, was the 37th most commonly prescribed medication in the United States, with more than 15.8 million combined branded and generic prescriptions in 2023

• Phase 1 clinical trial planned for mid-2026

ESTERO, FLORIDA / ACCESS Newswire / January 20, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the filing of a new provisional patent application with the United States Patent and Trademark Office (USPTO). The application, titled “A Sublingual Powder Formulation of Alprazolam and Methods of Use Thereof,” covers the first-ever sublingual powder formulation of alprazolam, the active pharmaceutical ingredient (API) in the widely prescribed anti-anxiety medication Xanax®. This development represents a series of sublingual powder-based therapeutic alternatives the Company intends to commercialize via the FDA’s 505(b)(2) regulatory pathway. Aspire’s strategic pipeline focuses on reformulating approved therapeutics to address unmet needs where no powder alternatives currently exist.

Alprazolam is a standard-of-care generic benzodiazepine medication taken by millions of patients globally for the management of anxiety disorders and panic attacks. While effective, the traditional oral administration of alprazolam tablets typically requires considerable time to take effect, often 30 minutes or more – as the pill must pass through the digestive system and liver before entering the bloodstream.

Advancing Pharmacokinetic Performance With Aspire’s Sublingual Formulation

The patent filing seeks protection for Aspire’s advanced sublingual delivery system. This technology is engineered to optimize the pharmacokinetic performance of alprazolam by improving its absorption into the bloodstream, increasing bioavailability, and significantly accelerating the speed of onset compared to traditional oral tablets. Alprazolam is widely prescribed – ranking as the 37th most common medication in the U.S. with over 15.8 million prescriptions in 2023, combined branded and generic prescriptions, according to ClinCalc. Traditionally administered in tablet form, Aspire’s sublingual powder alprazolam is designed to provide a critical alternative for patients requiring rapid relief. By utilizing a unique sublingual mechanism of action, the Company’s formulation allows the drug to be absorbed rapidly under the tongue. This method is intended to bypass the gastrointestinal tract and first-pass metabolism, potentially reducing the onset of action from approximately half-an-hour to just minutes, offering a transformational solution for patients requiring immediate relief during acute episodes.

CEO Commentary

“Today marks another vital milestone as we introduce another unique formulation of a widely utilized therapeutic,” said Kraig Higginson, Interim CEO of Aspire. “We believe this dosage form could offer patients a faster onset of action, which is crucial for managing acute panic attacks or severe anxiety episodes where swift relief is essential. Furthermore, it provides a much-needed solution for adult patients who suffer from dysphagia or have difficulty swallowing traditional capsules and tablets. By applying our technology to alprazolam, we are not inventing a new drug; we are making an existing, proven drug potentially work faster and more effectively.”

Higginson added, “This initiative follows the recent positive FDA response regarding our high-dose aspirin candidate and aligns with our broader strategy to expand our pipeline of 505(b)(2) branded products.”

About Alprazolam

Alprazolam is a benzodiazepine indicated for the management of generalized anxiety disorder (GAD), panic disorders, and symptoms of depression. While the first generic immediate-release tablets were FDA-approved in 1993, the market has lacked a fast-acting powder formulation. Aspire’s 505(b)(2) strategy aims to bridge this gap by leveraging the established safety profile of alprazolam while introducing a superior delivery mechanism.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; Aspire’s acetylsalicylic acid sublingual powder, 162 mg (OTASA) is an investigational new drug and has not been approved for marketing for any indication, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.

Contact:
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

New streamlined, mobile-optimized shopping experience, allows consumers to purchase BUZZ BOMB™ directly, access exclusive promotions and engage with the brand through educational and lifestyle content highlighting the benefits of sublingual delivery

ESTERO, FL / ACCESS Newswire / January 21, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted patent-pending delivery technology, is proud to announce the launch of a comprehensive brand redesign for its flagship caffeine product, BUZZ BOMB™. This strategic rebranding initiative introduces a new logo, sleek, modern website and eye-catching product packaging, reflecting the product’s capabilities and Aspire Biopharma’s commitment to cutting-edge science.

Enhanced Digital Experience
The new BUZZ BOMB™ website, now live at https://buzzbombcaffeine.com, offers a seamless, user-friendly experience ensuring customers can quickly and efficiently access their favorite energy solution. This upgraded shopping experience provides detailed product information, and an intuitive e-commerce interface, bringing a user-friendly, modern experience to consumers looking to bring energy back into their everyday lives.

New BUZZ BOMB™ E-Commerce Website Landing Page

Bold New Packaging
The newly redesigned packaging features a modern bold aesthetic, utilizing a vibrant color palette and bold typography that visually communicate immediate impact and efficacy. This refreshed look is designed to stand out and clearly convey the product’s promise of rapid, sustained focus and energy for peak performance not only for athletes, but the everyday person looking for a boost. It’s modern and the future of everyday caffeine.

BUZZ BOMB™ Newly Designed Packaging

“Our goal was to create a visual identity that matches the power of the product inside,” said Kraig Higginson, Interim CEO of Aspire. “We are committed to providing our customers with carefully formulated products that deliver real results. We worked with Thistle Marketing and our brand team to completely reconceptualize our BUZZ BOMB™ brand identity. The new design elements perfectly capture the intensity and precision of the product experience, and our new website offers an elevated platform to connect with our audience and share our story.”

BUZZ BOMB™ Mixed Berry Packets on ordering page

BUZZ BOMB™ is committed to developing unique caffeine products that deliver immediate, reliable energy without compromise. The new aesthetic and digital experience underscore BUZZ BOMB™’s commitment to innovation and customer satisfaction, positioning the brand for significant new growth potential.

About BUZZ BOMB™
BUZZ BOMB™ is a proprietary sublingual caffeine supplement developed by Aspire Biopharma that features 50mg of caffeine and is currently offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha). Designed for athletes, professionals, and the everyday person needing a rapid cognitive boost, BUZZ BOMB® provides a precise dose of caffeine that bypasses the GI tract for faster onset and smoother energy. To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com.

About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; Aspire’s acetylsalicylic acid sublingual powder, 162 mg (OTASA) is an investigational new drug and has not been approved for marketing for any indication, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

ESTERO, FL / ACCESS Newswire / January 14, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced a reverse stock split of its issued and outstanding common stock, par value $0.01 per share, at a ratio of one (1) share of common stock for every forty (40) shares of common stock, that will become effective as of 12:01 a.m. (Eastern Time) on January 16, 2026 (the “Effective Date”). The Company’s common stock will begin trading on a split-adjusted basis when the market opens on January 16, 2026. At the Company’s Special Meeting of Stockholders held on November 4, 2025, the Company’s stockholders approved a proposal to authorize a reverse stock split of the Company’s Common Stock, at a ratio within the range of 1-for-5 to 1-for-40. The Company’s board of directors approved a 1-for-40 reverse split ratio, and on January 15, 2026, the Company will file a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect the reverse stock split effective January 16, 2026. The Company’s common stock will continue to trade on The Nasdaq Capital Market under the stock ticker “ASBP” but will trade under the new CUSIP number 738920 206.

The reverse stock split is being implemented to ensure the Company meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

As a result of the reverse stock split, each forty (40) pre-split shares of common stock outstanding will automatically combine into one (1) new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 158.8 million shares to approximately 4.0 million shares without taking into account fractional shares. No fractional shares will be issued as a result of the reverse stock split. All fractional shares will be rounded up to the nearest whole share on an individual participant level. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity (other than as a result of the rounding of shares to the nearest whole share in lieu of issuing fractional shares).

The Company’s transfer agent, Colonial Stock Transfer Company, Inc., which is also acting as the exchange agent for the reverse split, will send instructions to stockholders of record who hold stock certificates regarding the exchange of their old certificates for new certificates, should they wish to do so. Stockholders who hold their shares in brokerage accounts or “street name” are not required to take action to implement the exchange of their shares.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and

developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; Aspire’s acetylsalicylic acid sublingual powder, 162 mg (OTASA) is an investigational new drug and has not been approved for marketing for any indication, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial

ESTERO, FL / ACCESS Newswire / January 7, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the successful outcome of a Type B pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA). The meeting provided a clear regulatory roadmap for the Company’s investigational new drug, acetylsalicylic acid 162 mg sublingual powder (OTASA), designed for the emergency treatment of suspected acute myocardial infarction (heart attack).

The FDA’s written responses provide the necessary guidance to finalize the Company’s clinical and regulatory development strategy. Based on FDA’s feedback, Aspire anticipates completing a currently planned multicenter crossover clinical trial and then submitting a Section 505(b)(2) New Drug Application. The clinical trial will evaluate serum thromboxane B₂ (TxB₂) inhibition in 32 healthy volunteers, comparing OTASA (162 mg) against the current standard of care-two chewed 81 mg aspirin tablets.

“The FDA’s constructive feedback validates our development path and brings us one step closer to providing a faster-acting intervention for heart attack patients,” said Kraig Higginson, Interim CEO of Aspire. “Aligning with the Agency on our clinical requirements significantly de-risks our timeline and we believe the FDA’s response leaves the door open for Aspire to obtain breakthrough therapy status for our OTASA product. We believe OTASA has the potential to become the market-leading emergency treatment, and this regulatory clarity is a vital milestone as we engage in active discussions with potential commercial partners.”

Clinical Data Highlights
The pre-IND submission was supported by data from a pilot, proof-of-concept clinical trial demonstrating:

• Rapid Absorption: OTASA produced higher and faster mean plasma concentrations of acetylsalicylic acid (ASA) compared to chewed aspirin tablets.

• Rapid Platelet Inhibition: The sublingual formulation inhibited serum TxB₂-a key biomarker for platelet aggregation-within the first two minutes of administration.

• Safety Profile: In initial evaluations, the product was safe and well-tolerated, with no reported adverse events.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and

developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; Aspire’s acetylsalicylic acid sublingual powder, 162 mg (OTASA) is an investigational new drug and has not been approved for marketing for any indication, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.

Contact:

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

• In partnering with Aspire’s BUZZ BOMB™ brand, Ashley joins a decorated athlete and fitness trainer roster fueled by the brand’s industry-leading commitment to innovation

ESTERO, FL / ACCESS Newswire / December 18, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a leader in innovative supplement delivery systems, is proud to announce that professional ultra-marathoner and Ironman champion Ashley Paulson has joined Aspire as the official Brand Ambassador for BUZZ BOMB™, the Company’s premier sublingual caffeine product.

Ashley Paulson: Endurance Athlete and BUZZ BOMB™ Ambassador

Ashley Paulson is a world-class endurance athlete, coach, and inspirational fitness figure whose journey embodies resilience, consistency, and joy in movement. Since beginning marathons as a teenager, she has completed 130+ official marathons, 25+ Ironman-distance triathlons, multiple ultra triathlons, and numerous ultra marathons, including two 281.2-mile events and 6+ 100-mile races. Notably, Ashley has earned the title of 2022 Women’s Champion and 2023 Overall Champion at the iconic Badwater 135 (one of the most grueling endurance races in the world) and holds the female course record for the event.

“Ashley is the personification of high energy and relentless drive,” said Kraig Higginson, Interim CEO of Aspire Biopharma. “We didn’t just want a face for the brand; we wanted someone who truly relies on our technology to perform at the highest level possible. Ashley is that person.”

Higginson added, “Our Ambassadors play an important role in our brand ecosystem. They not only inspire and influence athletes, but they have also demonstrated their ability to create genuine connections with their followers around the world, directly informing and elevating our performance product through their unique insights and expertise.”

Beyond her extraordinary athletic accomplishments, Ashley is a dedicated mother of four and has maintained an active role in fitness instruction and community engagement for over 20 years. She has been a group fitness instructor, a charismatic on-camera talent for major platforms such as NordicTrack/iFIT, and a mentor who inspires others to overcome personal challenges. Her philosophy, often described as “funsistency,” blends joy with relentless consistency, encouraging individuals of all levels to pursue their goals with passion and perseverance.

A New Era of Instant Energy

Traditional caffeine sources, like coffee or energy drinks, can take as long as 45 minutes to process through the digestive system. BUZZ BOMB™ utilizes a sublingual delivery method, allowing the caffeine to be absorbed directly through the tissues in the mouth for a near-instant effect without the “jitters” or digestive upset often associated with liquid supplements.

“In the middle of a 100-mile race, I don’t have time to wait for a drink to kick in, and I certainly don’t want a heavy stomach,” said Ashley Paulson. “BUZZ BOMB™ is a game-changer for my training and racing. It’s fast, portable, and gives me immediate mental clarity exactly when I’m hitting a wall. I’m excited to partner with a brand that embraces a comprehensive approach to wellness.”

The Paulson BUZZ BOMB™ Partnership

The collaboration marks a significant step for Aspire Biopharma as it expands its reach into the high-performance athletics and fitness markets.

• Authentic Performance: Ashley’s lifestyle as a mother of four and an elite athlete requires a balance of sustained energy and quick recovery.

• Scientific Innovation: BUZZ BOMB™ aligns with Ashley’s preference for “clean” performance tools that prioritize efficiency.

• Community Engagement: Paulson will lead upcoming digital campaigns, share exclusive training content, and represent BUZZ BOMB™ at major endurance events throughout 2026.

Ashley has over 174,000 followers on Instagram, 23,000 followers on TikTok, and over12,000 on Facebook. The posts, videos and stories Ashley shares on her social media platforms are considered to be in the upper tier of performance for influencer engagement. Her followers include active individuals who are interested in fitness and who appreciate Ashley’s authentic, fun, and open communication style.

For more about Ashley Paulson, follow her on Instagram, TikTok and Facebook.

https://www.instagram.com/ashkickn/?hl=en,

https://www.tiktok.com/@ashkickn1

https://www.facebook.com/ashley.j.paulson/

About BUZZ BOMB™

BUZZ BOMB™ is a proprietary sublingual caffeine supplement developed by Aspire Biopharma that features 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha). Designed for athletes, professionals, and anyone needing a rapid cognitive boost, BUZZ BOMB^® provides a precise dose of caffeine that bypasses the GI tract for faster onset and smoother energy.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver supplements to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, received notice (the “Notice”) on December 11, 2025, from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Hearings Panel has granted the Company’s request to continue its listing on The Nasdaq Stock Market, subject to the Company meeting certain conditions upon transfer of its common stock to The Nasdaq Capital Market, including demonstrating compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) on or before January 30, 2026 and with Listing Rule 5550(b)(1) (the “Equity Rule”) on or before February 17, 2026.

In connection with the Notice, the Company will transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market effective as of the opening of business on December 15, 2025. The Company’s common stock will continue to be traded under the symbol “ASBP” and trading of its common stock will be unaffected by this transfer.

“We believe the extension granted by the Nasdaq Hearings Panel will allow us to finish executing on our plan to regain compliance with Nasdaq’s requirements,” said Kraig Higginson, Interim CEO of Aspire. “We expect the Company will cure the bid price and market value of listed shares deficiencies within the required time frame. We are undertaking substantial steps in an effort to recapitalize the balance sheet and set up the Company to deliver long term value to our shareholders.”

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

ESTERO, FL / ACCESS Newswire / December 4, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, today provides a business update for the quarter ended September 30, 2025.

Q3 2025 and Recent Highlights

• Expanded its scientific team with the addition of Mark J. Jaroszeski, PhD, a tenured professor in the Department of Medical Engineering at the University of South Florida. Dr. Jaroszeski, who holds a PhD in Engineering Science with a dissertation focused on mechanically facilitated cell-cell electrofusion. His expertise is expected to assist in further developing Aspire’s unique sublingual delivery technology.

• Submitted its Pre-IND meeting request and briefing package to the U.S. Food and Drug Administration (FDA). The submission concerns the Company’s lead product candidate, a fast-acting, high-dose sublingual aspirin formulation for the treatment of suspected acute myocardial infarction (AMI) and represents a significant milestone on the path to potential FDA approval. On November 13, 2025, the FDA responded positively to the request and stated it would provide written responses in lieu of a meeting no later than January 2, 2026.

• Participated in the CPHI Frankfurt trade show, the world’s largest pharmaceutical event. The Company engaged in numerous strategic discussions with global pharmaceutical companies regarding technical collaboration and licensing opportunities for its lead product candidate, a novel sublingual high-dose aspirin. The conference has led to several licensing opportunities that the Company is considering.

• Filed an omnibus patent application with the U.S. Patent and Trademark Office for its sublingual delivery technology. This application – which seeks patent protection of Aspire’s proprietary technology in a variety of classes of drugs and other substances–focuses exclusively on protecting the Company’s advanced sublingual drug delivery system, which is designed to enhance the pharmacokinetic performance of Active Pharmaceutical Ingredients (“APIs”) and other substances into the bloodstream, increasing bioavailability and improving speed of onset. The omnibus patent supplements the patent protections already provided by Aspire’s previously filed patents.

• Shared its pipeline progress and key milestones expected through the remainder of 2025 and early 2026. The company is focusing its pipeline on reformulating approved drugs for multi-billion-dollar markets by utilizing its disruptive, patent-pending sublingual delivery technology and anticipates filing as many as five to ten additional patents before the end of Q1 2026.

• Began its influencer marketing campaign designed to drive conversion, brand awareness and loyalty for its innovative BUZZ BOMB™ caffeine product. Featuring 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), BUZZ BOMB™ provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken as needed for immediate effect.

• Increased the production capacity of its BUZZ BOMB™ single dose caffeine supplement through a new manufacturing relationship with SupraNaturals, a well-established contract manufacturer of nutritional and dietary supplements. As part of this agreement, Aspire Biopharma announced an initial production order of two million servings (100,000 20-packs) of BUZZ BOMB™ caffeine supplement, marking a significant milestone in the Company’s expansion efforts. The new product will be available for sale just before Christmas.

• Published positive final data from its randomized, crossover bioavailability trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Aspire’s investigational new sublingual aspirin product compared to chewed uncoated aspirin tablets in healthy adults. The sublingual formulation begins to inhibit platelet aggregation in under two minutes, acting approximately four to five times as fast as chewed aspirin.

• Announced the successful launch and distribution of over 30,000 BUZZ BOMB™ sample four-packs, its new sublingual caffeine supplement, at FitCon and FitExpo, held August 1-3, in Salt Lake City and Anaheim, with an estimated combined attendance in excess of 70,000 people.

• Announced that the Company’s Board of Directors (Board) has appointed Kraig Higginson as interim Chief Executive Officer (CEO), effective July 24, 2025. Mr. Higginson serves as Chairman of the Board and previously served as CEO of Aspire for nearly four years.

• Buzz Bomb Caffeine Company LC, a wholly owned subsidiary of Aspire:

  • Unveiled its new e-commerce solution, buzzbombcaffeine.com with BUZZ BOMB™ as its featured launch product. This new seamless direct-to-consumer shopping experience allows consumers to order BUZZ BOMB™ on the Buzz Bomb platform and have them shipped directly to their door with access to exclusive promotions, and customer support. To celebrate the launch, customers who register for Buzz Bomb’s e-commerce site will have first access to special pricing, free shipping offers, and other promotions. The site features an introductory sample pack of four flavors as well as 30-packs in various flavors.

  • Announced positive initial consumer feedback from the Company’s sampling of its sublingual caffeine supplement, BUZZ BOMB™. featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar caffeine market to help athletes, fitness enthusiasts, and others wanting a lift to maximize their performance potential. Buzz Bomb™ provides nearly instant energy, in easy-to-use convenient packs, which can be taken easily and without the need for mixing with water or relying on unhealthy energy drinks or soda.

Anticipated Upcoming Milestones

• Sublingual High-dose Aspirin (Lead Program)

  • H1 2026: Target submission of New Drug Application (NDA).

• Sublingual ED medication

  • H1 2026: Finalize formulation and manufacture test product.

  • Mid-2026: Initiate Phase 1 pharmacokinetic (PK) clinical cross-over study.

Kraig Higginson, Interim CEO of Aspire Biopharma, commented:

“Our third-quarter results represent the blueprint for our future value creation. We have clinically proven the superiority of our technology with sublingual aspirin, de-risking the platform, and we have demonstrated our ability to execute commercially with Buzz Bomb Caffeine Company’s successful launch of BUZZ BOMB™.”

Higginson continued, “Looking ahead, investors can see a clear line of sight to a series of major, value-driving catalysts. The most significant is our targeted NDA submission for sublingual aspirin in the first half of 2026, which aims to disrupt a multi-billion-dollar market. This will be followed by the initiation of clinical studies for our sublingual ED and other programs, our entry points into some of the largest pharmaceutical markets in the world. Our ability to scale commercially is already being validated, as demonstrated by Buzz Bomb Caffeine Company’s second production order of two million servings of BUZZ BOMB™ to meet growing demand. We believe the accomplishments of this quarter have set the stage for a transformative period of growth, and the market has yet to fully recognize the value of the catalysts that lie directly ahead.”

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.

Contact

Brett Maas
Hayden IR: (646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR: (646)-755-7412
james@haydenir.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

ESTERO, FLORIDA / ACCESS Newswire / December 2, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, is pleased to announce that on November 3, 2025, it submitted its Pre-IND meeting request and briefing package to the U.S. Food and Drug Administration (FDA). The submission concerns the Company’s lead product candidate, a fast-acting, high-dose sublingual aspirin formulation for the treatment of suspected acute myocardial infarction (AMI) and represents a significant milestone on the path to potential FDA approval.

The Pre-IND meeting initiates formal dialogue with the FDA and is intended to gain agency guidance on the clinical development strategy and confirm the proposed 505(b)(2) regulatory pathway for Aspire’s sublingual aspirin. Gaining this clarity is a critical step toward the Company’s goal of submitting a New Drug Application (NDA).

“Our clinical data is not just promising; it’s a breakthrough in MCI treatment. We demonstrated that our sublingual formulation begins to inhibit platelet aggregation in under two minutes, acting approximately four to five times as fast as chewed aspirin,” said Kraig Higginson, Interim CEO of Aspire Biopharma. “This rapid action, confirmed with a statistical significance of p<0.02, represents a clear and potentially life-saving advantage over the current standard of care. In a heart attack, every second saved translates to preserved heart muscle. We are eager to present this compelling evidence to the FDA and define an efficient path to bring this superior treatment to patients.”

Aspire’s confidence is rooted in the breakthrough final results of its recent clinical trial. The study showed that Aspire’s investigational product produced significantly higher and more rapid mean plasma concentrations of acetylsalicylic acid (ASA), the active form of aspirin, compared to chewed aspirin tablets (p<0.05). This was demonstrated clearly in the recent trial by the lowered levels of serum thromboxane B2 (TxB2), a key biomarker for reduced platelet accumulation, within the first two minutes after dosing (p<0.02) with Aspire’s sublingual aspirin, acting approximately four to five times faster than chewed conventional aspirin. This rapid pharmacological action demonstrates a clear and clinically meaningful superiority over the current standard of care.

The product was also observed to be safe and well-tolerated. These results underscore the potential for Aspire’s sublingual aspirin to provide a more rapid and reliable treatment for the 800,000+ people in the U.S. who suffer a heart attack each year.

The Company intends to pursue a 505(b)(2) regulatory pathway for its sublingual aspirin product. This streamlined pathway allows the FDA to consider data from previous studies on an already-approved drug, such as aspirin, which can potentially reduce the time and cost of development.

This milestone for the lead aspirin program also serves as a key validation of Aspire’s versatile sublingual delivery platform, which is being applied to a pipeline of other high-value programs.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.

Contact

Brett Maas
Hayden IR: (646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR: (646)-755-7412
james@haydenir.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

ESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, has expanded its scientific team with the November 4, 2025 addition of Mark J. Jaroszeski, PhD, a tenured professor in the Department of Medical Engineering at the University of South Florida. Dr. Jaroszeski, who holds a PhD in Engineering Science with a dissertation focused on mechanically facilitated cell-cell electrofusion.

“Dr. Jaroszeski is recognized globally for his pioneering work in DNA and drug delivery, and we are honored to welcome him to the Aspire team,” said Kraig Higginson, Interim CEO of Aspire Biopharma. “He brings extensive experience in medical delivery systems that will be instrumental in advancing Aspire’s proprietary sublingual delivery technology. His insight and track record of innovation will play a critical role as we continue to develop and optimize our platform, building on our initial pipeline and extending these benefits to a broader range of generic medicines.”

Mark J. Jaroszeski, Ph.D., is Professor of Medical Engineering at the University of South Florida College of Engineering. Dr. Jaroszeski is a leading innovator in developing DNA/drug delivery technologies and methods to treat disease. He was one of the early pioneers performing in vivo electroporation during the early 1990’s, and was among the first researchers to develop basic electrodes and pulsing protocols to deliver chemotherapeutic agents to tumors in animal models in vivo, safely and effectively, with very strong anti-tumor effects. His work on the frontiers of DNA/drug delivery over the past 20 years laid the foundation for more than 100 current clinical trials using gene delivery. He holds 34 U.S. patents, 12 of which have been licensed to 7 companies. He is also currently Vice President of Research for EF Therapeutics, Inc., a start-up company focused on DNA delivery and translating it to the human and veterinary clinical markets. He has published 62 articles in peer-reviewed journals, two books and 11 book chapters, and presented at more than 114 conferences worldwide. He serves as a manuscript reviewer for 21 journals, as well as frequent reviewer for the National Institutes of Health. He has organized/chaired seven professional conferences, and is a delegate to the International Bioelectrics Consortium, a collection of research groups from about 15 countries.

About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.
Contact
Brett Maas
Hayden IR: (646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR: (646)-755-7412
james@haydenir.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire